A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

Objectives: The primary objective of this multicentre, prospective, observational study was to assess whether there is improvement in the patients’ quality of life under treatment with rivastigmine transdermal patch, as it is evaluated both by patients and their caregivers. Compliance to treatment a...

Full description

Bibliographic Details
Main Authors:	Vassileios Vagenas, Georgios S Vlachos, Nikoleta Vlachou, Dimitrios Liakopoulos, Michail E Kalaitzakis, Michail Vikelis
Format:	Article
Language:	English
Published:	SAGE Publishing 2015-06-01
Series:	SAGE Open Medicine
Online Access:	https://doi.org/10.1177/2050312115587795

Similar Items

USE OF A RIVASTIGMINE TRANSDERMIC PATCH IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE DEMENTIA
by: Lacramioara Perju Dumbrava, et al.
Published: (2009-03-01)

A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting
by: Ejaz Nazir, et al.

Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report
by: Yıldız Değirmenci, et al.
Published: (2016-12-01)

From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease
by: R. Reñé, et al.
Published: (2014-03-01)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
by: Gustavo Alves Andrade dos Santos, et al.

Characteristics of patients with Alzheimer&rsquo;s disease who switch to rivastigmine transdermal patches in routine clinical practice
by: L&oacute;pez-Pousa S, et al.
Published: (2013-01-01)

The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
by: Elena Evgenyevna Vasenina, et al.
Published: (2012-09-01)

Once-daily transdermal rivastigmine in the treatment of Alzheimer&rsquo;s disease
by: Andreas Wentrup, et al.
Published: (2008-11-01)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer&rsquo;s disease in daily practice
by: Seibert J, et al.
Published: (2012-04-01)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
by: Davide V Moretti, et al.
Published: (2014-07-01)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease
by: M.R. Farlow, et al.
Published: (2011-06-01)

Study of Rivastigmine-loaded Microemulsion-Based Gel for Transdermal Drug Delivery
by: Ling-Chun Tsai, et al.
Published: (2017)

Rivastigmine patch (Exelon patch) compared to melatonin patch in prevention of postoperative delirium in the elderly
by: Rania Maher Hussien, et al.
Published: (2020-08-01)

The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective
by: Michail Vikelis, et al.
Published: (2015-07-01)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
by: Yong Kyun Kim, et al.
Published: (2014-10-01)

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
by: Jose A Muñoz-Moreno, et al.
Published: (2017-01-01)

Rivastigmine in the treatment of Alzheimer's disease: an update
by: Maria Luisa Onor, et al.
Published: (2007-04-01)

Alginate-derived microneedle devices for transdermal delivery of rivastigmine - application in skin mimetic model
by: Tânia Marisa Teixeira Guimarães
Published: (2021)

Adverse drug events affecting medication persistence with rivastigmine patch application
by: Osada T, et al.
Published: (2018-07-01)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
by: Yatawara C, et al.
Published: (2021-02-01)

Sumatriptan transdermal iontophoretic patch (NP101-Zelrix&trade;): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine
by: Vikelis M, et al.
Published: (2012-09-01)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer’s Disease: A 24-Week, Open-Label, Multicenter Study in Japan
by: Kengo Ueda, et al.
Published: (2019-08-01)

Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases Tratamento da apatia na doença de Alzheimer com rivastigmina transdérmica: relato de três casos
by: Alessandra Lamas Granero, et al.
Published: (2010-03-01)

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
by: Lilly Mary L, et al.
Published: (2005-01-01)

Peeking into the future: Transdermal patches for the delivery of micronutrient supplements
by: Maria G. Grammatikopoulou, et al.
Published: (2021-09-01)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
by: Hideki Shimura, et al.
Published: (2021-02-01)

Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan
by: Tzu-Hua Chen, et al.
Published: (2017-06-01)

Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease
by: R. Blesa González, et al.
Published: (2011-01-01)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
by: E Loveman, et al.
Published: (2006-01-01)

Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study
by: Michail Vikelis, et al.
Published: (2017-05-01)

Transdermal iontophoresis patch with reverse electrodialysis
by: Joon Lee, et al.
Published: (2017-01-01)

FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF ATENOLOL
by: Uttam Budhathoki, et al.
Published: (2016-10-01)

Transdermal Patches for Delivery of Beta-Blockers
by: Rohaľová S., et al.
Published: (2021-07-01)

Formulation Study of Buprenorphine Transdermal Patch
by: Chang-Liang Liao, et al.
Published: (2008)

In Vitro Study of Transdermal Estradiol Patches
by: Tung, Wen Ming, et al.
Published: (1993)

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
by: Kyung Won Park, et al.
Published: (2017-01-01)

A clinicopathological study of the neuropsychiatric features of Parkinson's disease
by: Kalaitzakis, Michail Efstathioy
Published: (2008)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease
by: Yu Nakamura, et al.
Published: (2011-06-01)

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
by: Balmiki Ray, et al.
Published: (2020-03-01)

Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
by: Joseph L Micca, et al.
Published: (2014-12-01)